Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 7709252
Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
granted -
US 7709609
Tumor suppressor gene, p47ING3
granted -
US 7709007
Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
granted -
US 7704491
Recombinant human metapneumovirus and its use
granted -
US 7704509
Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
granted -
US 7700273
Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor
granted -
US 7700578
Capsule composition for use as immunogen against Campylobacter jejuni
granted -
US 7700600
Methods for treating cardiac arrhythmia
granted -
US 7696338
Immunotoxin fusion proteins and means for expression thereof
granted -
US 7691579
Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
granted -
US 7691386
Chimeric papillomavirus-like particles
granted -
US 7687610
Human chorionic gonadotropin superagonists
granted -
US 7682618
Generation of virus-like particles and use as panfilovirus vaccine
granted -
US 7683095
Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
granted -
US 7678828
Methods for the formulation and manufacture of artesunic acid for injection
granted -
US 7678569
Cloned genome of infectious hepatitis C virus strain HC-TN and uses thereof
granted -
US 7674777
Immunostimulatory nucleic acid molecules
granted -
US 7670806
ADP-ribosyl acceptor hydrolase 3 (ARH3) polypeptides and methods of use
granted -
US 7666404
Glanders/meliodosis vaccines
granted -
US 7666411
Methods of treating and preventing colitis involving IL-13 and NK-T cells
granted -
US 7666427
HIV vaccines based on Env of multiple clades of HIV
granted -
US 7666674
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
granted -
US 7666846
Cholesterol-containing compounds and their use as immunogens against Borrelia burgdorferi
granted -
US 7662397
Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
granted -
US 7662395
Method of enhancing a targeted immune response against tumors
granted -
US 7662999
Recognition of oligosaccharide molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases
granted -
US 7662394
Nucleic acids encoding chimeric Flavivirus immunogens comprising the Japanese encephalitis virus (JEV) PRM signal sequence
granted -
US 7662568
Immunoliposome-nucleic acid amplification (ILNAA) assay
granted -
US 7662573
Methods for evaluating osteoarthritis risk
granted -
US 7662592
Bacteriocin inducer peptides
granted -
US 7662619
Sol-fusin: use of GP64-6His to catalyze membrane fusion
granted -
US 7659081
Determination of AM-binding proteins and the association of adrenomedullin (AM) therewith
granted -
US 7658364
Ocular therapeutic agent delivery devices and methods for making and using such devices
granted -
US 7659115
Nucleic acid encoding human transductin-1 polypeptide
granted -
US 7655474
Trioxyethylene gold nanoclusters functionalized with a single DNA
granted -
US 7655247
Malaria vaccines
granted -
US 7655397
Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
granted -
US 7655752
TNF-Ξ± converting enzyme inhibitory agents and method of using same
granted -
US 7655694
Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury
granted -
US 7649028
Interim dental dressing and restorative material
granted -
US 7648701
Peptide composition as immunogen for the treatment of allergy
granted -
US 7641909
Avirulent, immunogenic flavivirus chimeras
granted -
US 7641906
Intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis
granted -
US 7638333
Anthrax vaccine
granted -
US 7638130
Truncated recombinant major outer membrane protein antigen (R56) of Orientia tsutsugamushi strains Karp, Kato and Gilliam and its use in antibody based detection assays and vaccines
granted -
US 7638134
Insertion sites in fowlpox vectors
granted -
US 7635476
Anti-hepatitis a virus antibodies
granted -
US 7635688
Development of a preventive vaccine for filovirus infection in primates
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory